视网膜母细胞瘤动脉内化疗现状  

Current status of intra-arterial chemotherapy for retinoblastoma

作　　者：孙凡淇 郭小璇 顾华丽[2] Sun Fanqi;Guo Xiaoxuan;Gu Huali(Capital Medical University Forth Clinical School,Beijing 100730,China;Department of Pediatrics,Beijing Tongren Hospital,Capital Medical University,Beijing 100730,China)

机构地区：[1]首都医科大学第四临床医学院,北京100730 [2]首都医科大学附属北京同仁医院儿科,北京100730

出　　处：《国际眼科纵览》2024年第6期476-480,共5页International Review of Ophthalmology

基　　金：首都卫生发展科研专项(2024-2-2056);北京市属医院科研培育计划(pX2022005);首都医科大学本科生科研创新项目(XSKY2024348)。

摘　　要：视网膜母细胞瘤(retinoblastoma,RB)是儿童常见的眼部恶性肿瘤,随着医学技术的不断进步和对患者生活质量的重视,其治疗方法也在不断的演进。近年来,动脉内化疗(intra-arterial chemotherapy,IAC)成为治疗RB的重要手段,其通过眼动脉给药实现肿瘤靶向局部化疗,显著提高了治疗效果并降低了全身不良反应。本文对IAC在RB治疗中技术操作、化疗药物(马法兰、卡铂、拓扑替康)、眼局部与全身不良反应、预后和局限性进行综述,以期为临床上IAC的改良和发展提供参考。Retinoblastoma(RB),a common malignant tumor of the eye in children,has been continuously evolving in its treatment methods as medical technology advances and greater attention is paid to patients'quality of life.In recent years,intra-arterial chemotherapy(IAC)has become an important treatment modality for RB,achieving targeted local chemotherapy of the tumor through ophthalmic artery drug delivery,significantly improving treatment outcomes and reducing systemic adverse reactions.This article provides a comprehensive review of the technical operation,chemotherapeutic drugs(melphalan,carboplatin,topotecan),eye and systemic adverse reactions,prognosis,and limitations of IAC in the treatment of RB,aiming to provide reference value for the improvement and development of IAC in clinical practice.

关 键 词：视网膜母细胞瘤 介入治疗 动脉内化疗 

分 类 号：R739.7[医药卫生—肿瘤]